Sequential multimodal treatments with chemotherapy and surgery for advanced soft tissue sarcoma may be associated with better survival than chemotherapy

IF 2.6 3区医学 Q1 MEDICINE, GENERAL & INTERNAL

Journal of the Formosan Medical Association Pub Date : 2025-01-01 DOI:10.1016/j.jfma.2024.03.007

Ching-Tso Chen , Hsing-Wu Chen , Wei-Hsin Lin , Pei-Ming Huang , Mong-Wei Lin , Ching-Yao Yang , Che-Yu Hsu , Chia-Chun Wang , Jen-Chieh Lee , Koping Chang , Kuo-Hao Huang , Ho-Min Chen , Tom Wei-Wu Chen , Rong-Sen Yang , Ruey-Long Hong

{"title":"Sequential multimodal treatments with chemotherapy and surgery for advanced soft tissue sarcoma may be associated with better survival than chemotherapy","authors":"Ching-Tso Chen , Hsing-Wu Chen , Wei-Hsin Lin , Pei-Ming Huang , Mong-Wei Lin , Ching-Yao Yang , Che-Yu Hsu , Chia-Chun Wang , Jen-Chieh Lee , Koping Chang , Kuo-Hao Huang , Ho-Min Chen , Tom Wei-Wu Chen , Rong-Sen Yang , Ruey-Long Hong","doi":"10.1016/j.jfma.2024.03.007","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>In patients with advanced soft tissue sarcoma (STS), surgery had been reported to be associated with superior overall survival (OS). Chemotherapy details for such patients were less reported, and whether multimodal treatment with surgery and chemotherapy provides extra survival benefit remains unclear.</div></div><div><h3>Methods</h3><div>We retrospectively reviewed patients with newly diagnosed advanced STS treated at National Taiwan University Hospital from January 1, 2011, to December 31, 2017. OS was calculated from the day of diagnosis of advanced STS to the day of death or last follow-up. Baseline patient characteristics and details regarding surgery and chemotherapy were recorded.</div></div><div><h3>Results</h3><div>A total of 545 patients were diagnosed with STS from 2011 to 2017, of which 226 patients had advanced STS. The median age was 54.7 years, and 54% of patients were women. Approximately 38% of patients with advanced STS underwent surgery and exhibited a trend of longer OS compared with who did not (median = 18.6 vs. 11.9 months, <em>p</em> = 0.083). In the chemotherapy subgroup, the benefit of surgery was more prominent (median = 21.9 vs. 16.5 months, <em>p</em> = 0.037). Patients who received chemotherapy prior to surgery exhibited numerically longer OS than those who underwent surgery first (median = 33.9 vs. 18.3 months, <em>p</em> = 0.155). After adjusting other clinical factors, chemotherapy remained an independent factor associated with favourable OS.</div></div><div><h3>Conclusion</h3><div>Surgery may be more beneficial for the patients who receive chemotherapy. Our results support evaluation of sequential multimodal treatments strategy including surgery and chemotherapy in patients with advanced <span>STS</span>.</div></div>","PeriodicalId":17305,"journal":{"name":"Journal of the Formosan Medical Association","volume":"124 1","pages":"Pages 73-78"},"PeriodicalIF":2.6000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of the Formosan Medical Association","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0929664624001529","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}

引用次数: 0

Abstract

Background

In patients with advanced soft tissue sarcoma (STS), surgery had been reported to be associated with superior overall survival (OS). Chemotherapy details for such patients were less reported, and whether multimodal treatment with surgery and chemotherapy provides extra survival benefit remains unclear.

Methods

We retrospectively reviewed patients with newly diagnosed advanced STS treated at National Taiwan University Hospital from January 1, 2011, to December 31, 2017. OS was calculated from the day of diagnosis of advanced STS to the day of death or last follow-up. Baseline patient characteristics and details regarding surgery and chemotherapy were recorded.

Results

A total of 545 patients were diagnosed with STS from 2011 to 2017, of which 226 patients had advanced STS. The median age was 54.7 years, and 54% of patients were women. Approximately 38% of patients with advanced STS underwent surgery and exhibited a trend of longer OS compared with who did not (median = 18.6 vs. 11.9 months, p = 0.083). In the chemotherapy subgroup, the benefit of surgery was more prominent (median = 21.9 vs. 16.5 months, p = 0.037). Patients who received chemotherapy prior to surgery exhibited numerically longer OS than those who underwent surgery first (median = 33.9 vs. 18.3 months, p = 0.155). After adjusting other clinical factors, chemotherapy remained an independent factor associated with favourable OS.

Conclusion

Surgery may be more beneficial for the patients who receive chemotherapy. Our results support evaluation of sequential multimodal treatments strategy including surgery and chemotherapy in patients with advanced STS.

查看原文本刊更多论文

对晚期软组织肉瘤进行化疗和手术的序贯多模式治疗可能比化疗带来更好的生存率。

背景：有报道称，对于晚期软组织肉瘤（STS）患者，手术治疗可提高总生存率（OS）。此类患者的化疗细节报道较少，手术和化疗的多模式治疗是否能带来额外的生存获益仍不清楚：我们回顾性研究了 2011 年 1 月 1 日至 2017 年 12 月 31 日期间在台湾大学医院接受治疗的新确诊晚期 STS 患者。OS的计算时间为晚期STS确诊之日至死亡之日或最后一次随访。记录了患者的基线特征以及手术和化疗的详细情况：2011年至2017年期间，共有545名患者确诊为STS，其中226名患者为晚期STS。中位年龄为54.7岁，54%的患者为女性。约38%的晚期STS患者接受了手术，与未接受手术的患者相比，他们的OS有延长的趋势（中位数=18.6个月 vs. 11.9个月，p=0.083）。在化疗亚组中，手术的益处更为显著（中位 = 21.9 个月 vs. 16.5 个月，p = 0.037）。与先接受手术的患者相比，手术前接受化疗的患者显示出更长的OS（中位数=33.9个月对18.3个月，p=0.155）。在调整了其他临床因素后，化疗仍然是与良好的OS相关的独立因素：结论：手术可能对接受化疗的患者更有利。我们的研究结果支持对晚期 STS 患者进行包括手术和化疗在内的序贯多模式治疗策略评估。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of the Formosan Medical Association 医学-医学：内科

CiteScore

6.50

自引率

6.20%

发文量

381

审稿时长

57 days

期刊介绍： Journal of the Formosan Medical Association (JFMA), published continuously since 1902, is an open access international general medical journal of the Formosan Medical Association based in Taipei, Taiwan. It is indexed in Current Contents/ Clinical Medicine, Medline, ciSearch, CAB Abstracts, Embase, SIIC Data Bases, Research Alert, BIOSIS, Biological Abstracts, Scopus and ScienceDirect. As a general medical journal, research related to clinical practice and research in all fields of medicine and related disciplines are considered for publication. Article types considered include perspectives, reviews, original papers, case reports, brief communications, correspondence and letters to the editor.